Obesity Treatment Market Research Report – Forecast to 2027

Global Obesity Treatment Market Research Report, by Type (Inactivity, Obesity gluten, Obesity), Diagnosis (Blood Tests, Physical Examination), Treatment (Medication, Surgery, Lifestyle Changes), End-Users (Hospitals, Clinics) - Global Forecast Till 2027

ID: MRFR/Pharma/4416-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Obesity is a disorder characterized by an excessive amount of body fat. The medical condition not only generates cosmetic concerns but is also related to various diseases and health problems, including heart diseases, diabetes, and others. A variety of treatment options are available in the market for obesity treatment, which ranges from medications to surgeries. Growing obese population and increasing acceptance of bariatric surgeries are expected to be the major drivers for the market growth during the forecast period. The Monash University stated that Australia recorded a burgeoning number of bariatric surgeries in 2015, accounting for approximately 15,000 procedures within the region. Moreover, the increasing demand for minimally invasive surgeries, rising awareness, and favorable reimbursement policies are expected to boost the market growth during the forecast period. However, factors such as high cost of surgery followed by the risks of infection and anesthesia allergy and low healthcare expenditure in the middle and low-income countries are estimated to restrain the market growth during the forecast period. According to a study published in the Obesity Surgery Journal in 2017, the mean total cost for bariatric procedures such as gastric bypass or adjustable gastric banding was estimated to be around USD 14,389.


The Global Obesity Treatment Market is expected to grow at an approximate CAGR of 16.7% during forecast period.

Figure 1- Global Obesity Treatment Market Share, by Region


 Obesity Treatment Market


Sources: Obesity Surgery journal, Eurostat, Monash University annual reports, press release, white paper, and company presentation


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Segmentation


The global obesity treatment market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the market is segmented into inactivity obesity, food obesity, anxiety obesity, venous obesity, atherogenic obesity, and gluten obesity. On the basis of diagnosis, the market is categorized into blood tests, physical examination, and others. The blood tests segment is sub-segmented into cholesterol test, liver function test, thyroid test, and others. The physical examination segment is sub-segmented into heart rate measurement, blood pressure measurement, and others. On the basis of treatment, the market is segmented into medication, surgery, lifestyle changes, and others. The medication segment is sub-segmented into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment is sub-segmented into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others. On the basis of end-user, the market is segmented into hospitals, clinics, pharmacies, and others.


Key players


Some of the key players for the global obesity treatment market are VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.


Research Methodology


 Methodology


Sources: Obesity Surgery journal, Eurostat, Monash University annual reports, press release, white paper, and company presentation


Regional Analysis


The Americas dominates the global market for obesity treatment due to an increasing obese population and presence of a well-developed healthcare sector. Moreover, factors such as changing lifestyle, the presence of developed economies, and increasing healthcare expenditure boost the market within the Americas.


Europe follows the Americas and stands second in the global obesity treatment market. The availability of funds for research, growing obese population, and increasing adoption of bariatric surgeries within the region are estimated to drive the market within the region. As per the Eurostat in 2016, more than half of the adults, accounting for 51.6% of the total population living within the European Union were estimated to be overweight. On a regional basis, Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market in developed economies such as Italy, the U.K., France, and others.


Asia Pacific is estimated to be the fastest growing region and provides huge opportunities for the market growth. This can be attributed to the increasing obese population, continuously developing economies, and a growing healthcare sector within the region.  From 2014–2015, the Australian Institute of Health and Welfare stated that approximately two-thirds, i.e., 63% of the Australian population, aged 18 or more, were estimated to be overweight or obese.


On the other hand, the Middle East and Africa holds the least share in the global obesity treatment market due to the presence of poor economies and stringent government policies, especially within the Africa region. A majority of the market of the Middle East and Africa is estimated to be held by the Middle East.


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   16.7% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-user.
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), and others.
  Key Market Opportunities

  • Growing obese population
  • Increasing acceptance of bariatric surgeries
  •   Key Market Drivers

  • Increasing demand for minimally invasive surgeries
  • Rising awareness
  • Favorable reimbursement policies


  • Frequently Asked Questions (FAQ) :


    On the basis of treatment, the Obesity Treatment Market is segmented into medication, surgery, lifestyle changes, and others.

    The Obesity Treatment Market is expected to exhibit a strong 16.7% CAGR over the forecast period till 2027.

    The growing prevalence of obesity is the major driver for the market.

    North America is the leading regional market for obesity treatment.

    Leading players in the Obesity Treatment Market include Novo Nordisk, Arena Pharmaceuticals, and Allergan, among others.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Obesity Treatment Market, by Type

    6.1 Introduction

    6.2 Inactivity Obesity

    Market Estimates & Forecast, 2020–2027

    6.3 Food Obesity

    Market Estimates & Forecast, 2020–2027

    6.4 Anxiety Obesity

    Market Estimates & Forecast, 2020–2027

    6.5 Venous Obesity

    Market Estimates & Forecast, 2020–2027

    6.6 Atherogenic Obesity

    Market Estimates & Forecast, 2020–2027

    6.7 Gluten Obesity

    Market Estimates & Forecast, 2020–2027

    Chapter 7. Global Obesity Treatment Market, by Diagnosis

    7.1 Introduction

    7.2 Blood Tests

    Market Estimates & Forecast, 2020–2027

    7.2.1 Cholesterol Tests

    7.2.2 Liver Function Tests

    7.2.3 Thyroid Tests

    7.3 Physical Examination

    Market Estimates & Forecast, 2020–2027

    7.3.1 Heart Rate Measurement

    7.3.2 Blood Pressure Measurement

    7.3.3 Others

    7.4 Others

    Chapter 8. Global Obesity Treatment Market, by Treatment

    8.1 Introduction

    8.2 Medication

    Market Estimates & Forecast, 2020–2027

    8.2.1 Orlistat

    8.2.2 Lorcaserin

    8.2.3 Phentermine and Topiramate

    8.2.4 Liraglutide

    8.2.5 Others

    8.3 Surgery

    Market Estimates & Forecast, 2020–2027

    8.3.1 Gastric Bypass Surgery

    8.3.2 Laparoscopic Adjustable Gastric Banding (LAGB)

    8.3.3 Gastric Sleeve

    8.3.4 Biliopancreatic Diversion

    8.3.5 Gastric Sleeve

    8.3.6 Others

    8.4 Lifestyle Changes

    8.5 Others

    Chapter 9. Global Obesity Treatment Market, by End-User

    9.1 Introduction

    9.2 Hospitals

    Market Estimates & Forecast, 2020–2027

    9.3 Clinics

    Market Estimates & Forecast, 2020–2027

    9.4 Pharmacies

    Market Estimates & Forecast, 2020–2027

    9.5 Others

    Chapter 10. Global Obesity Treatment Market, by Region

    10.1 Introduction

    10.2 America

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K.

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 VIVUS, Inc.

    12.1.1 Company Overview

    12.1.2 Type Overview

    12.1.3 Financials

    12.2.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Arena Pharmaceuticals, Inc.

    12.2.1 Company Overview

    12.2.2 Type Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 F. Hoffmann-La Roche, Ltd.

    12.3.1 Company Overview

    12.3.2 Type Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Novo Nordisk A/S

    12.4.1 Company Overview

    12.4.2 Type/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Orexigen Therapeutics, Inc.

    12.5.1 Company Overview

    12.5.2 Type Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Allergan

    12.6.1 Company Overview

    12.6.2 Type Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Cousin Biotech

    12.7.1 Overview

    12.7.2 Type Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 EnteroMedics, Inc.

    12.8.1 Overview

    12.8.2 Type Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Johnson & Johnson Services, Inc.

    12.9.1 Overview

    12.9.2 Type Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Medtronic

    12.10.1 Overview

    12.10.2 Type Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 USGI Medical, Inc.

    12.11.1 Overview

    12.11.2 Type Overview

    12.11.3 Financials

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.12 Mediflex Surgical Products

    12.12.1 Overview

    12.12.2 Type Overview

    12.12.3 Financials

    12.12.4 Key Developments

    12.12.5 SWOT Analysis

    12.13 Covidien plc

    12.13.1 Overview

    12.13.2 Type Overview

    12.13.3 Financials

    12.13.4 Key Developments

    12.13.5 SWOT Analysis

    12.14 Olympus Corporation

    12.14.1 Overview

    12.14.2 Type Overview

    12.14.3 Financials

    12.14.4 Key Developments

    12.14.5 SWOT Analysis

    12.15 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Global Obesity Treatment Market

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Obesity Treatment Industry Synopsis, 2020–2027

    Table 2 Global Obesity Treatment Market Estimates & Forecast, 2020–2027, (USD Million)

    Table 3 Global Obesity Treatment Market, by Region, 2020–2027, (USD Million)

    Table 4 Global Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 5 Global Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 6 Global Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 7 Global Obesity Treatment Market, by End-User, 2020–2027, (USD Million

    Table 8 North America Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 9 North America Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 10 North America Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 11 North America Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 12 U.S. Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 13 U.S. Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 14 U.S. Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 15 U.S. Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 16 Canada Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 17 Canada Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 18 Canada Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 19 Canada Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 20 South America Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 21 South America Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 22 South America Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 23 South America Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 24 Europe Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 25 Europe Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 26 Europe Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 27 Europe Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 28 Western Europe Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 29 Western Europe Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 30 Western Europe Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 31 Western Europe Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 32 Eastern Europe Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 33 Eastern Europe Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 34 Eastern Europe Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 35 Eastern Europe Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 36 Asia Pacific Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 37 Asia Pacific Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 38 Asia Pacific Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 39 Asia Pacific Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    Table 40 The Middle East & Africa Obesity Treatment Market, by Type, 2020–2027, (USD Million)

    Table 41 The Middle East & Africa Obesity Treatment Market, by Diagnosis, 2020–2027, (USD Million)

    Table 42 The Middle East & Africa Obesity Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 43 The Middle East & Africa Obesity Treatment Market, by End-User, 2020–2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Obesity Treatment Market

    Figure 3 Market Dynamics for Global Obesity Treatment Market

    Figure 4 Global Obesity Treatment Market Share, by Type 2020

    Figure 5 Global Obesity Treatment Market Share, by Diagnosis 2020

    Figure 6 Global Obesity Treatment Market Share, by Treatment, 2020

    Figure 7 Global Obesity Treatment Market Share, by End-User, 2020

    Figure 8 Global Obesity Treatment Market Share, by Region, 2020

    Figure 9 North America Obesity Treatment Market Share, by Country, 2020

    Figure 10 Europe Obesity Treatment Market Share, by Country, 2020

    Figure 11 Asia Pacific Obesity Treatment Market Share, by Country, 2020

    Figure 12 The Middle East & Africa Obesity Treatment Market Share, by Country, 2020

    Figure 13 Global Obesity Treatment Market: Company Share Analysis, 2020 (%)

    Figure 14 VIVUS, Inc.: Key Financials

    Figure 15 VIVUS, Inc.: Segmental Revenue

    Figure 16 VIVUS, Inc.: Geographical Revenue

    Figure 17 Arena Pharmaceuticals, Inc.: Key Financials

    Figure 18 Arena Pharmaceuticals, Inc.: Segmental Revenue

    Figure 19 Arena Pharmaceuticals, Inc.: Geographical Revenue

    Figure 20 F. Hoffmann-La Roche, Ltd.: Key Financials

    Figure 21 F. Hoffmann-La Roche, Ltd.: Segmental Revenue

    Figure 22 F. Hoffmann-La Roche, Ltd.: Geographical Revenue

    Figure 23 Novo Nordisk A/S: Key Financials

    Figure 24 Novo Nordisk A/S: Segmental Revenue

    Figure 25 Novo Nordisk A/S: Geographical Revenue

    Figure 26 Orexigen Therapeutics, Inc.: Key Financials

    Figure 27 Orexigen Therapeutics, Inc.: Segmental Revenue

    Figure 28 Orexigen Therapeutics, Inc.: Geographical Revenue

    Figure 29 Allergan: Key Financials

    Figure 30 Allergan: Segmental Revenue

    Figure 31 Allergan: Geographical Revenue

    Figure 32 Cousin Biotech: Key Financials

    Figure 33 Cousin Biotech: Segmental Revenue

    Figure 34 Cousin Biotech: Geographical Revenue

    Figure 35 EnteroMedics, Inc.: Key Financials

    Figure 36 EnteroMedics, Inc.: Segmental Revenue

    Figure 37 EnteroMedics, Inc.: Geographical Revenue

    Figure 38 Johnson & Johnson Services, Inc.: Key Financials

    Figure 39 Johnson & Johnson Services, Inc.: Segmental Revenue

    Figure 40 Johnson & Johnson Services, Inc.: Geographical Revenue

    Figure 41 Medtronic: Key Financials

    Figure 42 Medtronic: Segmental Revenue

    Figure 43 Medtronic: Geographical Revenue

    Figure 44 USGI Medical, Inc.: Key Financials

    Figure 45 USGI Medical, Inc.: Segmental Revenue

    Figure 46 USGI Medical, Inc.: Geographical Revenue

    Figure 47 Mediflex Surgical Products: Key Financials

    Figure 48 Mediflex Surgical Products: Segmental Revenue

    Figure 49 Mediflex Surgical Products: Geographical Revenue

    Figure 50 Covidien plc: Key Financials

    Figure 51 Covidien plc: Segmental Revenue

    Figure 52 Covidien plc: Geographical Revenue

    Figure 53 Olympus Corporation: Key Financials

    Figure 54 Olympus Corporation: Segmental Revenue

    Figure 55 Olympus Corporation: Geographical Revenue